Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives (Q37959062)

25 August 2017

title

Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives (English)

1 reference

25 August 2017

author name string

Alejandro de la Sierra

series ordinal

1

1 reference

25 August 2017

language of work or name

1 reference

1 December 2011

1 reference

Expert Review of Cardiovascular Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

9

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

1585-1591

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

25 August 2017

1 reference

Management of antihypertensive drugs in three European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Modern treatment of patients at risk: still a HOPE for ACE inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Can we achieve a greater reduction of cardiovascular mortality and morbidity in patients already treated with renin-angiotensin system blockers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Priority actions for the non-communicable disease crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Worldwide prevalence of hypertension: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Shattuck Lecture. The hypertension paradox--more uncontrolled disease despite improved therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Supramaximal dose of candesartan in proteinuric renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

Stemming the global tsunami of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.11.164

21 January 2018

Identifiers

DOI

10.1586/ERC.11.164

1 reference

25 August 2017

1 reference